Clinical Trial Integrity and COVID-19


Statement to EB148 on the COVID-19 response


FACT SHEET: Impact and Knowledge of COVID-19 and related measures in rural Kenyan households

COVID-19 Technology Access Pool

Letter to Dr Tedros: The Challenge of Access to Insulin Amidst COVID-19

The fight against COVID-19: let’s make public investments count for people


Response to European Consultation on Intellectual Property

IP in a Post-pandemic World

Annual Report 2022

Diagnostics to Address Antimicrobial Resistance


Licensing and Access to Health Technologies

The TRIPS Agreement Laid Bare

HAI Statement to Intergovernmental Negotiating Body

Statement to WHA75 – Health Emergencies

Response to European Consultation on Compulsory Licensing


Medicine Pricing and Access in Europe

Eudamed and CTIS: Lessons from EudraCT

Transparency and Medicines Policy in the EU

Statement to WHA74 on GSPOA

HAI Statement on The Oslo Medicines Initiative at the WHO Virtual Consultation with Non-State Actors, 31 March 2021

Response to EU’s HERA Initiative Consultation

Transparency, Accountability and Access to Medicines: European Projects 2021

Statement to EB148 on WHO reform: involvement of non-State actors in WHO’s governing bodies

Letter to Dr Tedros: Leadership and Advocacy for C-TAP

Statement to EB148 on global strategy and plan of action on public health, innovation and intellectual property


Joint HTA Assessment in Europe: Progress in 2020

Cross-country Cooperation Schemes: A fair-weather solution to the issue of access to medicines in Europe?

European Commission Intellectual Property Action Plan

Driving Change in Access to Medicines – Annual Report 2019